BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, Wang S, Zhang C, Yuan X, Xu Z, Huang L, Fu JL, Li Y, Zhang Y, Yao WQ, Liu T, Song J, Sun L, Yang F, Zhang X, Zhang B, Shi M, Meng F, Song Y, Yu Y, Wen J, Li Q, Mao Q, Maeurer M, Zumla A, Yao C, Xie WF, Wang FS. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther 2021;6:58. [PMID: 33568628 DOI: 10.1038/s41392-021-00488-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang Y, Li X, Yang L. Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment. Stem Cell Res Ther 2022;13:410. [PMID: 35962458 DOI: 10.1186/s13287-022-03034-4] [Reference Citation Analysis]
2 Liu C, Xiao K, Xie L. Advances in mesenchymal stromal cell therapy for acute lung injury/acute respiratory distress syndrome. Front Cell Dev Biol 2022;10:951764. [DOI: 10.3389/fcell.2022.951764] [Reference Citation Analysis]
3 Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, Nguyen GH, Le PTT, Hoang VT, Forsyth NR, Heke M, Nguyen LT. Stem cell-based therapy for human diseases. Signal Transduct Target Ther 2022;7:272. [PMID: 35933430 DOI: 10.1038/s41392-022-01134-4] [Reference Citation Analysis]
4 Chen CY, Chen WC, Hsu CK, Chao CM, Lai CC. The clinical efficacy and safety of mesenchymal stromal cells for patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. J Infect Public Health 2022;15:896-901. [PMID: 35849852 DOI: 10.1016/j.jiph.2022.07.001] [Reference Citation Analysis]
5 Aghayan HR, Salimian F, Abedini A, Fattah Ghazi S, Yunesian M, Alavi-Moghadam S, Makarem J, Majidzadeh-A K, Hatamkhani A, Moghri M, Danesh A, Haddad-Marandi MR, Sanati H, Abbasvandi F, Arjmand B, Azimi P, Ghavamzadeh A, Sarrami-Forooshani R. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment. Stem Cell Res Ther 2022;13:365. [PMID: 35902979 DOI: 10.1186/s13287-022-02953-6] [Reference Citation Analysis]
6 Manoharan R, Kore RA, Mehta JL. Mesenchymal stem cell treatment for hyperactive immune response in patients with COVID-19. Immunotherapy 2022. [PMID: 35855633 DOI: 10.2217/imt-2021-0245] [Reference Citation Analysis]
7 Shi L, Zheng Y, Cheng Z, Ji N, Niu C, Wang Y, Huang T, Li R, Huang M, Chen X, Shu L, Wu M, Deng K, Wei J, Wang X, Cao Y, Yan J, Feng G. One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment. Stem Cell Res Ther 2022;13:321. [PMID: 35842684 DOI: 10.1186/s13287-022-02972-3] [Reference Citation Analysis]
8 Rossello-Gelabert M, Gonzalez-Pujana A, Igartua M, Santos-Vizcaino E, Hernandez RM. Clinical progress in MSC-based therapies for the management of severe COVID-19. Cytokine Growth Factor Rev 2022:S1359-6101(22)00050-8. [PMID: 35843774 DOI: 10.1016/j.cytogfr.2022.07.002] [Reference Citation Analysis]
9 Grégoire C, Layios N, Lambermont B, Lechanteur C, Briquet A, Bettonville V, Baudoux E, Thys M, Dardenne N, Misset B, Beguin Y. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Front Immunol 2022;13:932360. [DOI: 10.3389/fimmu.2022.932360] [Reference Citation Analysis]
10 Li YE, Ajoolabady A, Dhanasekaran M, Ren J. Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy. Pharmacol Res 2022;182:106334. [PMID: 35779816 DOI: 10.1016/j.phrs.2022.106334] [Reference Citation Analysis]
11 Kirkham AM, Bailey AJM, Monaghan M, Shorr R, Lalu MM, Fergusson DA, Allan DS. Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval-FASTER Approval. Stem Cells Transl Med 2022:szac038. [PMID: 35758400 DOI: 10.1093/stcltm/szac038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cuevas-González MV, Cuevas-González JC. Stem cells as an option for the treatment of COVID-19. World J Clin Cases 2022; 10(18): 6338-6340 [DOI: 10.12998/wjcc.v10.i18.6338] [Reference Citation Analysis]
13 Zhang M, Yan X, Shi M, Li R, Pi Z, Ren X, Wang Y, Yan S, Wang Y, Jin Y, Wang X. Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis. Glob Health Res Policy 2022;7:19. [PMID: 35733229 DOI: 10.1186/s41256-022-00251-5] [Reference Citation Analysis]
14 Arias M, Oliveros H, Lechtig S, Bustos R. Biologics in COVID-19 So Far: Systematic Review. Pharmaceuticals 2022;15:783. [DOI: 10.3390/ph15070783] [Reference Citation Analysis]
15 Javed A, Karki S, Sami Z, Khan Z, Shree A, Sah BK, Ghosh S, Saxena S, Chen H. Association between Mesenchymal Stem Cells and COVID-19 Therapy: Systematic Review and Current Trends. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/9346939] [Reference Citation Analysis]
16 Yasamineh S, Kalajahi HG, Yasamineh P, Gholizadeh O, Youshanlouei HR, Matloub SK, Mozafari M, Jokar E, Yazdani Y, Dadashpour M. Spotlight on therapeutic efficiency of mesenchymal stem cells in viral infections with a focus on COVID-19. Stem Cell Res Ther 2022;13:257. [PMID: 35715852 DOI: 10.1186/s13287-022-02944-7] [Reference Citation Analysis]
17 Li C. Strengthening regulations, recent advances and remaining barriers in stem cell clinical translation in China: 2015-2021 in review. Pharmacol Res 2022;182:106304. [PMID: 35710062 DOI: 10.1016/j.phrs.2022.106304] [Reference Citation Analysis]
18 Kay AG, Fox JM, Hewitson JP, Stone AP, Robertson S, James S, Wang X, Kapasa E, Yang XB, Genever PG. CD317-Positive Immune Stromal Cells in Human “Mesenchymal Stem Cell” Populations. Front Immunol 2022;13:903796. [DOI: 10.3389/fimmu.2022.903796] [Reference Citation Analysis]
19 Zhu YG, Shi MM, Monsel A, Dai CX, Dong X, Shen H, Li SK, Chang J, Xu CL, Li P, Wang J, Shen MP, Ren CJ, Chen DC, Qu JM. Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study. Stem Cell Res Ther 2022;13:220. [PMID: 35619189 DOI: 10.1186/s13287-022-02900-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, McGuigan P, Jackson C, Boyle R, McFerran J, McDowell C, Campbell C, McFarland M, Smythe J, Thompson J, Williams B, Curley G, Laffey JG, Clarke M, McAuley DF, O'Kane C. Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial. Trials 2022;23:401. [PMID: 35562778 DOI: 10.1186/s13063-022-06220-0] [Reference Citation Analysis]
21 Farhangnia P, Dehrouyeh S, Safdarian AR, Farahani SV, Gorgani M, Rezaei N, Akbarpour M, Delbandi A. Recent Advances in Passive Immunotherapies for COVID-19: The Evidence-Based Approaches and Clinical Trials. International Immunopharmacology 2022. [DOI: 10.1016/j.intimp.2022.108786] [Reference Citation Analysis]
22 Karyana M, Djaharuddin I, Rif'ati L, Arif M, Choi MK, Angginy N, Yoon A, Han J, Josh F, Arlinda D, Narulita A, Muchtar F, Bakri RA, Irmansyah S. Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial. Stem Cell Res Ther 2022;13:134. [PMID: 35365239 DOI: 10.1186/s13287-022-02812-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Jovic D, Yu Y, Wang D, Wang K, Li H, Xu F, Liu C, Liu J, Luo Y. A Brief Overview of Global Trends in MSC-Based Cell Therapy. Stem Cell Rev Rep 2022. [PMID: 35344199 DOI: 10.1007/s12015-022-10369-1] [Reference Citation Analysis]
24 Yao W, Shi L, Zhang Y, Dong H, Zhang Y. Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives. Stem Cell Res Ther 2022;13:124. [PMID: 35321737 DOI: 10.1186/s13287-022-02810-6] [Reference Citation Analysis]
25 Rebelatto CLK, Senegaglia AC, Franck CL, Daga DR, Shigunov P, Stimamiglio MA, Marsaro DB, Schaidt B, Micosky A, de Azambuja AP, Leitão CA, Petterle RR, Jamur VR, Vaz IM, Mallmann AP, Carraro Junior H, Ditzel E, Brofman PRS, Correa A. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Res Ther 2022;13:122. [PMID: 35313959 DOI: 10.1186/s13287-022-02796-1] [Reference Citation Analysis]
26 Ringdén O, Moll G, Gustafsson B, Sadeghi B. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome. Front Immunol 2022;13:839844. [DOI: 10.3389/fimmu.2022.839844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
27 Xu R, Feng Z, Wang FS. Mesenchymal stem cell treatment for COVID-19. EBioMedicine 2022;77:103920. [PMID: 35279630 DOI: 10.1016/j.ebiom.2022.103920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Sauer T, Facchinetti G, Kohl M, Kowal JM, Rozanova S, Horn J, Schmal H, Kwee I, Schulz AP, Hartwig S, Kassem M, Habermann JK, Gemoll T. Protein Expression of AEBP1, MCM4, and FABP4 Differentiate Osteogenic, Adipogenic, and Mesenchymal Stromal Stem Cells. Int J Mol Sci 2022;23:2568. [PMID: 35269711 DOI: 10.3390/ijms23052568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Chen L, Qu J, Kalyani FS, Zhang Q, Fan L, Fang Y, Li Y, Xiang C. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-021-04096-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Lu K, Geng ST, Tang S, Yang H, Xiong W, Xu F, Yuan Q, Xiao X, Huang R, Liang H, Chen Z, Qian C, Li Y, Wang S. Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19. Stem Cell Res Ther 2022;13:61. [PMID: 35130977 DOI: 10.1186/s13287-022-02743-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Zhao F, Ma Q, Yue Q, Chen H. SARS-CoV-2 Infection and Lung Regeneration. Clin Microbiol Rev 2022;:e0018821. [PMID: 35107300 DOI: 10.1128/cmr.00188-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Xia Y, Lang T, Niu Y, Wu X, Zhou O, Dai J, Bao L, Yang K, Zou L, Fu Z, Geng G. Phase I trial of human umbilical cord-derived mesenchymal stem cells for treatment of severe bronchopulmonary dysplasia. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.02.001] [Reference Citation Analysis]
33 Karakaş N, Üçüncüoğlu S, Uludağ D, Karaoğlan BS, Shah K, Öztürk G. Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives. Cells 2022;11:465. [DOI: 10.3390/cells11030465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Niknam Z, Jafari A, Golchin A, Danesh Pouya F, Nemati M, Rezaei-Tavirani M, Rasmi Y. Potential therapeutic options for COVID-19: an update on current evidence. Eur J Med Res 2022;27:6. [PMID: 35027080 DOI: 10.1186/s40001-021-00626-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
35 Masterson CH, Ceccato A, Artigas A, Dos Santos C, Rocco PR, Rolandsson Enes S, Weiss DJ, McAuley D, Matthay MA, English K, Curley GF, Laffey JG. Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges. Intensive Care Med Exp 2021;9:61. [PMID: 34970706 DOI: 10.1186/s40635-021-00424-5] [Reference Citation Analysis]
36 Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, Song J, Huang L, Xu Z, Fu JL, Li Y, Xu R, Li TT, Dong J, Cai J, Li G, Xie Y, Shi M, Li Y, Zhang Y, Xie WF, Wang FS. Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. EBioMedicine 2021;75:103789. [PMID: 34963099 DOI: 10.1016/j.ebiom.2021.103789] [Reference Citation Analysis]
37 Xu D, Su Y, Xu Q, Huang T, Chen Z, Zhang T. Uniform iron oxide nanoparticles reduce the required amount of polyethylenimine in the gene delivery to mesenchymal stem cells. Nanotechnology 2021;33. [PMID: 34874301 DOI: 10.1088/1361-6528/ac4066] [Reference Citation Analysis]
38 Arabpour E, Khoshdel S, Tabatabaie N, Akhgarzad A, Zangiabadian M, Nasiri MJ. Stem Cells Therapy for COVID-19: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:737590. [PMID: 34912818 DOI: 10.3389/fmed.2021.737590] [Reference Citation Analysis]
39 Wang W, Wang Y, Tang Z, Chen Y, Liu Z, Duan H, Zhong Z, He F. Mesenchymal stem cells prevent ovariectomy-induced osteoporosis formation in mice through intraosseous vascular remodeling. Biochem Biophys Res Commun 2021;582:64-71. [PMID: 34689107 DOI: 10.1016/j.bbrc.2021.10.033] [Reference Citation Analysis]
40 da Silva KN, Pinheiro PCG, Gobatto ALN, Passos RDH, Paredes BD, França LSA, Nonaka CKV, Barreto-Duarte B, Araújo-Pereira M, Tibúrcio R, Cruz FF, Martins GLS, Andrade BB, de Castro-Faria-Neto HC, Rocco PRM, Souza BSF. Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report. Front Med (Lausanne) 2021;8:767291. [PMID: 34869480 DOI: 10.3389/fmed.2021.767291] [Reference Citation Analysis]
41 Aslan A, Aslan C, Zolbanin NM, Jafari R. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia (Nathan) 2021;13:14. [PMID: 34872623 DOI: 10.1186/s41479-021-00092-9] [Reference Citation Analysis]
42 Jia Y, Dietrich CF, Sun S. EUS-guided cell transplantation: Planting seeds of hope. Endosc Ultrasound 2021;10:401-3. [PMID: 34975038 DOI: 10.4103/EUS-D-21-00220] [Reference Citation Analysis]
43 Kulus M, Sibiak R, Stefańska K, Zdun M, Wieczorkiewicz M, Piotrowska-Kempisty H, Jaśkowski JM, Bukowska D, Ratajczak K, Zabel M, Mozdziak P, Kempisty B. Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues-Origins, Characteristics, Signaling Pathways, and Clinical Trials. Cells 2021;10:3278. [PMID: 34943786 DOI: 10.3390/cells10123278] [Reference Citation Analysis]
44 Abbas M, Alqahtani MS, Almohiy HM, Alqahtani FF, Alhifzi R, Jambi LK. The Potential Contribution of Biopolymeric Particles in Lung Tissue Regeneration of COVID-19 Patients. Polymers (Basel) 2021;13:4011. [PMID: 34833310 DOI: 10.3390/polym13224011] [Reference Citation Analysis]
45 Loke XY, Imran SAM, Tye GJ, Wan Kamarul Zaman WS, Nordin F. Immunomodulation and Regenerative Capacity of MSCs for Long-COVID. Int J Mol Sci 2021;22:12421. [PMID: 34830303 DOI: 10.3390/ijms222212421] [Reference Citation Analysis]
46 Šikić J, Planinić Z, Matišić V, Friščić T, Molnar V, Jagačić D, Vujičić L, Tudorić N, Postružin Gršić L, Ljubičić Đ, Primorac D. COVID-19: The Impact on Cardiovascular System. Biomedicines 2021;9:1691. [PMID: 34829920 DOI: 10.3390/biomedicines9111691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Wang MY, Zhou TY, Zhang ZD, Liu HY, Zheng ZY, Xie HQ. Current therapeutic strategies for respiratory diseases using mesenchymal stem cells. MedComm (2020) 2021;2:351-80. [PMID: 34766151 DOI: 10.1002/mco2.74] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Zanirati G, Provenzi L, Libermann LL, Bizotto SC, Ghilardi IM, Marinowic DR, Shetty AK, Da Costa JC. Stem cell-based therapy for COVID-19 and ARDS: a systematic review. NPJ Regen Med 2021;6:73. [PMID: 34750382 DOI: 10.1038/s41536-021-00181-9] [Reference Citation Analysis]
49 Bhalerao A, Raut S, Noorani B, Mancuso S, Cucullo L. Molecular Mechanisms of Multi-Organ Failure in COVID-19 and Potential of Stem Cell Therapy. Cells 2021;10:2878. [PMID: 34831101 DOI: 10.3390/cells10112878] [Reference Citation Analysis]
50 Fang J, Feng C, Chen W, Hou P, Liu Z, Zuo M, Han Y, Xu C, Melino G, Verkhratsky A, Wang Y, Shao C, Shi Y. Redressing the interactions between stem cells and immune system in tissue regeneration. Biol Direct 2021;16:18. [PMID: 34670590 DOI: 10.1186/s13062-021-00306-6] [Reference Citation Analysis]
51 Xu Z, Huang Y, Zhou J, Deng X, He W, Liu X, Li Y, Zhong N, Sang L. Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS. Front Immunol 2021;12:738697. [PMID: 34659231 DOI: 10.3389/fimmu.2021.738697] [Reference Citation Analysis]
52 Zhang C, Jin H, Wen YF, Yin G. Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Front Public Health 2021;9:729559. [PMID: 34650951 DOI: 10.3389/fpubh.2021.729559] [Reference Citation Analysis]
53 Lu Q, Huang S, Meng X, Zhang J, Yu S, Li J, Shi M, Fan H, Zhao Y. Mechanism of Phosgene-Induced Acute Lung Injury and Treatment Strategy. Int J Mol Sci 2021;22:10933. [PMID: 34681591 DOI: 10.3390/ijms222010933] [Reference Citation Analysis]
54 Shaw TD, Krasnodembskaya AD, Schroeder GN, Zumla A, Maeurer M, O'Kane CM. Mesenchymal Stromal Cells: an Antimicrobial and Host-Directed Therapy for Complex Infectious Diseases. Clin Microbiol Rev 2021;:e0006421. [PMID: 34612662 DOI: 10.1128/CMR.00064-21] [Reference Citation Analysis]
55 Li Y, Zhao W, Liu J, Chen Z, Lv Q, Zhang Z. Immunotherapy Summary for Cytokine Storm in COVID-19. Front Pharmacol 2021;12:731847. [PMID: 34603047 DOI: 10.3389/fphar.2021.731847] [Reference Citation Analysis]
56 Wang J, Shi P, Chen D, Wang S, Wang P, Feng X, Zhang L. Research Status of the Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of COVID-19-Related Pneumonia: A Systematic Review and Meta-Analysis. Stem Cells Dev 2021;30:947-69. [PMID: 34416823 DOI: 10.1089/scd.2021.0179] [Reference Citation Analysis]
57 Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, Izcovich A, Mangala S, Ge L, Han MA, Agoritsas T, Arnold D, Ávila C, Chu DK, Couban R, Cusano E, Darzi AJ, Devji T, Foroutan F, Ghadimi M, Khamis A, Lamontagne F, Loeb M, Miroshnychenko A, Motaghi S, Murthy S, Mustafa RA, Rada G, Rochwerg B, Switzer C, Vandvik PO, Vernooij RW, Wang Y, Yao L, Guyatt GH, Brignardello-Petersen R. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ 2021;374:n2231. [PMID: 34556486 DOI: 10.1136/bmj.n2231] [Reference Citation Analysis]
58 Cheng Q, Chen J, Jia Q, Fang Z, Zhao G. Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. Aging (Albany NY) 2021;13:21866-902. [PMID: 34531332 DOI: 10.18632/aging.203522] [Reference Citation Analysis]
59 Primorac D, Čemerin M, Matišić V, Molnar V, Strbad M, Girandon L, Zenić L, Knežević M, Minger S, Polančec D. Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment. Pharmaceutics 2021;13:1481. [PMID: 34575557 DOI: 10.3390/pharmaceutics13091481] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Shetty AK, Shetty PA, Zanirati G, Jin K. Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS. NPJ Regen Med 2021;6:53. [PMID: 34504110 DOI: 10.1038/s41536-021-00161-z] [Reference Citation Analysis]
61 Shi L, Wang L, Xu R, Zhang C, Xie Y, Liu K, Li T, Hu W, Zhen C, Wang FS. Mesenchymal stem cell therapy for severe COVID-19. Signal Transduct Target Ther 2021;6:339. [PMID: 34497264 DOI: 10.1038/s41392-021-00754-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Galderisi U, Peluso G, Di Bernardo G. Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years? Stem Cell Rev Rep 2021. [PMID: 34398443 DOI: 10.1007/s12015-021-10231-w] [Reference Citation Analysis]
63 Taechangam N, Kol A, Arzi B, Borjesson DL. Multipotent Stromal Cells and Viral Interaction: Current Implications for Therapy. Stem Cell Rev Rep 2021. [PMID: 34347271 DOI: 10.1007/s12015-021-10224-9] [Reference Citation Analysis]
64 Chen L, Qu J, Mei Q, Chen X, Fang Y, Chen L, Li Y, Xiang C. Small extracellular vesicles from menstrual blood-derived mesenchymal stem cells (MenSCs) as a novel therapeutic impetus in regenerative medicine. Stem Cell Res Ther 2021;12:433. [PMID: 34344458 DOI: 10.1186/s13287-021-02511-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Shi J, Zhou J, Zhang X, Hu W, Zhao JF, Wang S, Wang FS, Zhang JY. Single-Cell Transcriptomic Profiling of MAIT Cells in Patients With COVID-19. Front Immunol 2021;12:700152. [PMID: 34394094 DOI: 10.3389/fimmu.2021.700152] [Reference Citation Analysis]
66 O Ercelen N, Pekkoc-Uyanik KC, Alpaydin N, Gulay GR, Simsek M. Clinical experience on umbilical cord mesenchymal stem cell treatment in 210 severe and critical COVID-19 cases in Turkey. Stem Cell Rev Rep 2021. [PMID: 34319510 DOI: 10.1007/s12015-021-10214-x] [Reference Citation Analysis]
67 da Silva KN, Gobatto ALN, Costa-Ferro ZSM, Cavalcante BRR, Caria ACI, de Aragão França LS, Nonaka CKV, de Macêdo Lima F, Lopes-Pacheco M, Rocco PRM, de Freitas Souza BS. Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19? Stem Cell Res Ther 2021;12:425. [PMID: 34315546 DOI: 10.1186/s13287-021-02502-7] [Reference Citation Analysis]
68 Fernández-Francos S, Eiro N, González-Galiano N, Vizoso FJ. Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives. Int J Mol Sci 2021;22:7850. [PMID: 34360616 DOI: 10.3390/ijms22157850] [Reference Citation Analysis]
69 Adas G, Cukurova Z, Yasar KK, Yilmaz R, Isiksacan N, Kasapoglu P, Yesilbag Z, Koyuncu ID, Karaoz E. The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial. Cell Transplant 2021;30:9636897211024942. [PMID: 34180719 DOI: 10.1177/09636897211024942] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
70 Feng G, Shi L, Huang T, Ji N, Zheng Y, Lin H, Niu C, Wang Y, Li R, Huang M, Chen X, Shu L, Wu M, Deng K, Wei J, Wang X, Cao Y, Yan J. Human Umbilical Cord Mesenchymal Stromal Cell Treatment of Severe COVID-19 Patients: A 3-Month Follow-Up Study Following Hospital Discharge. Stem Cells Dev 2021;30:773-81. [PMID: 34044609 DOI: 10.1089/scd.2021.0015] [Reference Citation Analysis]
71 Kim M, Knoepfler PS. Anticipated impact of stem cell and other cellular medicine clinical trials for COVID-19. Regen Med 2021;16:525-33. [PMID: 34114493 DOI: 10.2217/rme-2021-0025] [Reference Citation Analysis]
72 Kulus J, Kulus M, Stefańska K, Sobolewski J, Piotrowska-Kempisty H, Mozdziak P, Kempisty B. SARS-CoV-2 Genetic Variability and Non-Specific Immunity Associated with the Use of Different BCG Strains-A Molecular and Clinical Approach. Vaccines (Basel) 2021;9:639. [PMID: 34200951 DOI: 10.3390/vaccines9060639] [Reference Citation Analysis]
73 Kaffash Farkhad N, Reihani H, Sedaghat A, Moghadam AA, Moghadam AB, Tavakol-Afshari J. Are mesenchymal stem cells able to manage cytokine storm in COVID-19 patients? A review of recent studies. Regen Ther 2021;18:152-60. [PMID: 34124322 DOI: 10.1016/j.reth.2021.05.007] [Reference Citation Analysis]
74 Inchingolo AD, Dipalma G, Inchingolo AM, Malcangi G, Santacroce L, D'Oria MT, Isacco CG, Bordea IR, Candrea S, Scarano A, Morandi B, Del Fabbro M, Farronato M, Tartaglia GM, Balzanelli MG, Ballini A, Nucci L, Lorusso F, Taschieri S, Inchingolo F. The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. Antioxidants (Basel) 2021;10:881. [PMID: 34072708 DOI: 10.3390/antiox10060881] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
75 Serrano-Aroca Á, Takayama K, Tuñón-Molina A, Seyran M, Hassan SS, Pal Choudhury P, Uversky VN, Lundstrom K, Adadi P, Palù G, Aljabali AAA, Chauhan G, Kandimalla R, Tambuwala MM, Lal A, Abd El-Aziz TM, Sherchan S, Barh D, Redwan EM, Bazan NG, Mishra YK, Uhal BD, Brufsky A. Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era. ACS Nano 2021;15:8069-86. [PMID: 33826850 DOI: 10.1021/acsnano.1c00629] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 53.0] [Reference Citation Analysis]
76 Wang W, Lei W, Jiang L, Gao S, Hu S, Zhao ZG, Niu CY, Zhao ZA. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment. J Transl Med 2021;19:198. [PMID: 33971907 DOI: 10.1186/s12967-021-02862-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
77 Carvalho JL, Silva-Carvalho AE, Garcez EM, Saldanha-Araujo F. Commentary: Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment. Front Immunol 2021;12:682195. [PMID: 33995424 DOI: 10.3389/fimmu.2021.682195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Maeurer M, Ramalho R, Wang FS, Zumla A. Host-directed therapies for COVID-19. Curr Opin Pulm Med 2021;27:205-9. [PMID: 33629969 DOI: 10.1097/MCP.0000000000000769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
79 Harrell CR, Popovska Jovicic B, Djonov V, Volarevic V. Molecular Mechanisms Responsible for Mesenchymal Stem Cell-Based Treatment of Viral Diseases. Pathogens 2021;10:409. [PMID: 33915728 DOI: 10.3390/pathogens10040409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]